Logo

AMLX

Amylyx Pharmaceuticals, Inc.

AMLX

Amylyx Pharmaceuticals, Inc. • NASDAQ
$14.98 ▼ -0.13% (-0.02)
Market Cap $1.25 B
52w High $16.96
52w Low $2.60
Dividend Yield 0%
P/E -8.37
Volume 338.96K
Outstanding Shares 83.13M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $16.172M ▼ $-34.386M ▲ 0% $-0.37 ▲ $-34.266M ▲
Q2-2025 $0 $42.716M ▲ $-41.443M ▼ 0% $-0.46 ▼ $-41.302M ▼
Q1-2025 $0 ▲ $37.803M ▼ $-35.907M ▲ 0% ▼ $-0.42 ▲ $-37.647M ▲
Q4-2024 $-665K ▼ $39.989M ▼ $-37.546M ▲ 5.646K% ▲ $-0.55 ▲ $-40.494M ▲
Q3-2024 $416K $75.268M $-72.704M -17.477K% $-1.07 $-75.44M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $343.99M ▲ $362.741M ▲ $30.745M ▲ $331.996M ▲
Q2-2025 $180.826M ▼ $194.598M ▼ $26.721M ▲ $167.877M ▼
Q1-2025 $204.068M ▲ $219.676M ▲ $18.259M ▼ $201.417M ▲
Q4-2024 $176.501M ▼ $193.634M ▼ $28.869M ▼ $164.765M ▼
Q3-2024 $234.395M $250.713M $54.51M $196.203M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-34.386M ▲ $-30.368M ▼ $5.236M ▼ $191.606M ▲ $167.093M ▲ $-30.392M ▼
Q2-2025 $-41.443M ▼ $-25.248M ▲ $22.994M ▲ $-31K ▼ $-1.679M ▲ $-25.265M ▲
Q1-2025 $-35.907M ▲ $-39.824M ▲ $-43.659M ▼ $65.662M ▲ $-17.624M ▼ $-39.835M ▲
Q4-2024 $-37.546M ▲ $-59.008M ▼ $64.98M ▲ $110K ▲ $5.557M ▲ $-59.028M ▼
Q3-2024 $-72.704M $-41.57M $38.816M $80K $-2.438M $-41.551M

Five-Year Company Overview

Income Statement

Income Statement Amylyx’s income statement shows a young biotech that briefly reached profitability but has returned to being a loss‑making, development‑stage company. Revenue ramped up only recently and remains modest after the withdrawal of its ALS drug, so the business no longer has a meaningful commercial engine. Operating and net results swung from losses in earlier years, to a short period of profit, and then back to sizeable losses as the company reset its strategy and leaned into R&D rather than sales growth. In simple terms, the company is currently spending much more on research, overhead, and its strategic pivot than it brings in from product sales.

Balance Sheet

Balance Sheet The balance sheet is relatively clean and equity‑funded. Assets, especially cash, increased sharply after the IPO and later financing activity, giving the company a solid cushion compared with its earlier, pre‑IPO years when it had a thin asset base and negative equity. Debt is essentially negligible, so the capital structure is simple and not weighed down by interest obligations. While the total asset base has come down from its peak as cash has been used to fund operations, Amylyx still sits on a meaningful cash reserve and positive equity, which provides flexibility but will be drawn down if losses continue.

Cash Flow

Cash Flow Cash flow patterns reflect a typical clinical‑stage biotech: cash is flowing out to fund trials and operations. Operating cash flow has been negative in most years, with only a brief period near breakeven when the ALS product was on the market. Free cash flow closely tracks operating cash flow because capital spending is minimal, which means cash burn is driven almost entirely by R&D and overhead rather than large facility investments. Based on the research summary, management believes the current cash balance can support operations into the middle of the decade, but this assumes no major cost overruns and continued discipline on spending.

Competitive Edge

Competitive Edge Amylyx’s competitive position is in transition. The company no longer has an approved, marketed drug after the Relyvrio withdrawal, which removes a key commercial advantage it briefly held in ALS. Its current moat is being rebuilt around a small but focused pipeline. Avexitide could be first‑in‑class for post‑bariatric hypoglycemia, where there are no approved treatments and existing options are off‑label and imperfect. In ALS, AMX0114 offers a differentiated, targeted approach, but faces a crowded and highly challenging field with many competing mechanisms. Overall, Amylyx currently competes more on scientific differentiation and rare‑disease focus than on commercial scale, brand, or established market share.

Innovation and R&D

Innovation and R&D Innovation and R&D are now the core of Amylyx’s story. The company is concentrating on diseases where the biology is relatively well understood and where patients have few or no good treatment options. Avexitide, a GLP‑1 receptor blocker for post‑bariatric hypoglycemia, and AMX0114, an antisense therapy for ALS, both aim at clearly defined biological targets and carry supportive FDA designations, which can speed development and review. The strategy is “modality‑agnostic,” meaning the company is willing to use different types of drug technologies to match each disease. The flip side is that the pipeline is still early or mid‑stage, with significant scientific and regulatory risk, and outcomes for the lead programs over the next few years will heavily influence the long‑term value of the R&D portfolio.

Summary

Amylyx is a biotech in reset mode: it moved from a pre‑revenue R&D company, to a briefly commercial one with Relyvrio, and back to a development‑stage profile after withdrawing that product. Financially, it has a history of losses, a short-lived period of profit, and now renewed operating losses funded by a solid but finite cash balance and little to no debt. Strategically, the company is leaning into a focused pipeline in rare and serious diseases, with potential first‑in‑class and highly targeted therapies that could be meaningful if trials succeed. The main strengths are its clean balance sheet, cash runway, and concentrated innovation around clear biological targets; the main risks are the lack of current revenue, dependence on a small number of pipeline assets, and the inherent uncertainty of clinical and regulatory outcomes over the next few years.

NEWS

November 28, 2025 · 6:40 PM UTC

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Read more

November 13, 2025 · 2:40 PM UTC

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Read more

November 11, 2025 · 6:00 PM UTC

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Read more

November 6, 2025 · 7:00 AM UTC

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Read more

November 4, 2025 · 7:45 AM UTC

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Read more